NewsRoom Articles - Page 4 of 206

FridayMay 23, 2025 10:30 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network of psychiatric clinics. The acquisition brings profitability and is expected to be accretive to both revenue and EBITDA. Kadima’s founder and medical director, Dr. David Feifel, a leader in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer. NRx’s pipeline includes investigational drugs for suicidal bipolar depression and chronic pain. HOPE is targeting 30 clinic acquisitions by the end of 2025, projecting $100M in annual revenue. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics, Inc., a medical…

FridayMay 23, 2025 9:00 am

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows

Intelligent Bio Solutions remains on track for a 2025 U.S. launch of its non-invasive Intelligent Fingerprinting Drug Screening System. The company’s FDA 510(k) submission included validation studies showing 94.1% accuracy in detecting opiates through fingerprint sweat. INBS is already active in 24 countries, with over 450 commercial accounts globally, and adoption growing across diverse industries, including logistics, mining, retail, and marine operations. The firm is expanding its distributor network to support localized growth ahead of its U.S. market entry. Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, is preparing for its expected U.S.…

ThursdayMay 22, 2025 10:30 am

Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization

AVERSA Fentanyl has potential to become the world’s first opioid pain patch with abuse deterrent properties, CEO states in report Nutriband and Kindeva Drug Delivery have formalized a strong product-development partnership and long-term commitment Other key steps outlined as company works to develop, scale-up manufacturing process to bring Aversa technology closer toward commercialization In a recent report to shareholders, Nutriband (NASDAQ: NTRB) CEO Gareth Sheridan shared significant company achievements and milestones as well as his expectations for 2025 (https://ibn.fm/9K5zT). At the center of the company’s positive outlook for future is noteworthy progress made toward the commercialization of its proprietary Aversa technology, including…

ThursdayMay 22, 2025 10:00 am

Experts Say New Test for Brain Tumors is a Game-Changer

Researchers have developed a novel brain tumor test that surgical experts have dubbed a game changer. This is because the test collapses the needed time to obtain an accurate diagnosis to just hours rather than multiple weeks as has been the case. Surgeons say this new approach can dramatically improve the treatment and care that patients receive after this “ultra-fast” diagnostic tool is used. University of Nottingham scientists, together with a team from the NHS Trust of University of Nottingham Hospitals (NUH) developed this method. Their approach has caused a stir in UK hospitals and many are collecting data on…

WednesdayMay 21, 2025 9:00 am

Adageis Offers Easy-to-Use AI-Driven Solution to Help Healthcare Providers Unlock High-Value Care, Maximize Revenue

Adageis delivers a user-friendly platform that helps providers identify high-value services while improving care quality. The company’s patented ProActive Care Platform leverages AI to shift providers from fee-for-service to value-based care models. The system integrates seamlessly with major EHR platforms to enhance operations without disrupting workflows. Adageis supports over 260,000 patient lives and expects that figure to more than double by the end of Q2 2025. The company is helping providers better understand insurance contract value and advocate for appropriate reimbursement. For healthcare practices navigating the shift toward value-based care, the complexity of insurance contracts, quality metrics, and data reporting…

TuesdayMay 20, 2025 10:00 am

Researchers Discover Potential Missing Connection Between EBV and Multiple Sclerosis

For many years, the scientific community has known that the risk of Multiple Sclerosis is markedly higher among people that have been exposed to the Epstein-Barr virus, the virus which causes infectious mononucleosis (commonly called “mono”). However, it isn’t clear why only a tiny fraction of individuals exposed to “mono” go on to develop MS. Now new research has uncovered a likely explanation why the vast majority of individuals exposed to the mono virus don’t go on to develop multiple sclerosis. According to the study, those who escape MS despite having ever suffered a mono infection have a gene mutation…

TuesdayMay 20, 2025 9:45 am

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Targets Global Sales Growth with Multilingual Digital Rollout

Medical technology company Intelligent Bio Solutions has launched Arabic, Italian, and Spanish websites to support expansion into key international markets. The move opens digital access to over 1.4 billion people across Latin America, the Middle East, and Southern Europe. The rollout aligns with increased demand for non-invasive workplace drug testing and compliance tools. INBS’s flagship fingerprint sweat-based drug screening system is currently used by over 450 clients in 24 countries. The company plans a U.S. market launch in 2025 as it continues to develop additional biosensor applications. Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive…

TuesdayMay 20, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central nervous system disorders. The company’s lead candidate, NRX-100 (preservative free IV ketamine), NDA in process with the FDA, has been granted Fast Track designation by the FDA for acute suicidal depression, and a patent for this novel formulation has been filed with the U.S. Patent and Trademark Office. NRX-101 (oral D-cycloserine/lurasidone), has received FDA Breakthrough Therapy designation, expediting its development. HOPE Therapeutics, NRx’s interventional psychiatry subsidiary, is targeting $100M in forward looking revenue by year-end 2025, through development of a national clinic network treating suicidal depression,…

MondayMay 19, 2025 2:30 pm

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. After undergoing ibogaine and DMT therapy in Mexico in 2018, Luttrell described the experience as transformative, helping him confront trauma and save his marriage. Now in Congress, he’s pushing for science-based, medically supervised access to Schedule I drugs like ibogaine, psilocybin, and MDMA. Joined by fellow veterans in office, including Rep. Dan Crenshaw (R-Texas) and Rep. Jack Bergman (R-Mich.), Luttrell…

MondayMay 19, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results

Q1 milestones are representative of Soligenix’s commitment to advance its pipeline of therapeutic candidates, focusing on areas with significant unmet medical needs. The company noted positive interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) treatment. Soligenix announced the release of a publication describing the preclinical efficacy of CiVax(TM), a thermostabilized subunit vaccine against SARS-CoV-2. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases, recently announced its financial results for the first quarter of 2025, alongside a summary of the company’s latest accomplishments (https://ibn.fm/OMQmM). These milestones are representative of Soligenix’s continued…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Progressing with FDA Clearance for Fingerprint Drug Testing as Global Demand Grows

Nutriband Inc. (NASDAQ: NTRB) Charts Path to Commercialization

Experts Say New Test for Brain Tumors is a Game-Changer

Adageis Offers Easy-to-Use AI-Driven Solution to Help Healthcare Providers Unlock High-Value Care, Maximize Revenue

Researchers Discover Potential Missing Connection Between EBV and Multiple Sclerosis

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Targets Global Sales Growth with Multilingual Digital Rollout

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Soligenix Inc. (NASDAQ: SNGX) Reports Q1 Milestones, Financial Results

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search